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OBJECTIVE: To estimate the current prevalence of prenatal 
exposure to methamphetamines and other drugs of abuse 
among infants born in Utah and compare the results with 
those of a maternal substance abuse prevalence study per-
formed in 1991 in the same geographic area. 
METHODS: Thirteen well baby nurseries in calendar year 
2000 and six neonatal intensive care units (NICUs) in 
2001-2002 collected anonymous meconium samples and 
associated, but nonidentifiable, demographic data on con-
secutively born infants. Samples were screened by enzyme 
immunoassay and confirmed by gas chromotography/ 
mass spectroscopy for methamphetamines, cannabinoids, 
and benzoylecognine. 
RESULTS: Meconium samples were collected from 1202 
well baby nursery infants and 317 NICU infants. There 
were no significant differences in the rates of positivity for 
methamphetamines (0.6% versus 0.4%) or marijuana 
(2.9% versus 1.8%) between the 1991 and 2000/2001 studies. 
Cocaine prevalence declined from 1.1% in 1991 to 0.3% in 
2000/2001 (P = .04). The prevalence of positivity for any of 
these three drugs declined over the lO-year period from 
4.4% to 2.4% (P = .02). The prevalence for positivity for any 
of these three drugs was higherin the NICUs (4.7%) than in 
the well baby nurseries (1.9%, P = .008). 
CONCLUSION: The rate of drug-positive infants declined 
during the decade of the 1990s in a geographic area that is 
experiencing a sharp rise in the use of methamphetamine 
among women of childbearing age. Further studies that 
focus on women of childbearing age who use methamphet-
amine may help determine factors that impact their drug 
use during pregnancy and after the infant is born. 
(Obstet Gynecol 2003;102:27-30. © 2003 by The Ameri-
can College of Obstetricians and Gynecologists.) 
Research clearly shows that infants born to drug- and 
alcohol-abusing mothers are at risk for developmental 
and behavioral problems resulting from prenatal expo-
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sure and dysfunctional parenting.1,2 It is important for 
prenatal and pediatric care providers to be aware of 
evolving trends in maternal substance abuse to improve 
detection and facilitate intervention. During the 1990s, 
the use of methamphetamine increased in prevalence 
throughout the West and Southwest United States, and 
there is evidence that the problem is currently reaching 
into rural and urban areas of the South and Midwest. 3 In 
1991,0.38% of the total admissions for substance abuse 
treatment in Utah were for methamphetamine addiction. 
By 2001, that percentage had risen to 18.5%, outpacing 
marijuana as the primary illicit drug of choice for patients 
in treatment.4 In 2001, 37% of the female treatment 
population in Utah were treated for addiction to meth-
amphetamine, compared with 1.2% in 1992. This study 
was undertaken to investigate the impact of the alarming 
and changing patterns of drug abuse in women of child-
bearing age in Utah on the newborn population. 
The first objective of this study was to estimate the 
current prevalence of prenatal exposure to methamphet-
amines and other drugs of abuse among infants born in 
northern Utah. The second objective was to compare the 
results of this study with those of a maternal substance 
abuse prevalence study performed in 1991 in the same 
geographic area.5 
MATERIALS AND METHODS 
After approval from the respective institutional review 
boards, 13 well baby nurseries in calendar year 2000 and 
six neonatal intensive care units (NICUs) in 2001-2002 
collected anonymous meconium samples and associated, 
but nonidentifiable, demographic data on consecutively 
born infants. These hospitals were all located along the 
Wasatch Front in northern Utah, where 78% of the 
state's births occur. Of the 17 well baby nurseries in this 
area, the 13 with the highest birth volume participated, 
and six of the seven NICUs in Utah participated. A 
history of maternal drug and alcohol use was recorded if 
this information was documented in the medical record. 
All samples were sent to United States Drug Testing 
Laboratories Inc., where they were screened by enzyme 
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Table 1. Drug Prevalence Rates 
2000/2001 Meconium 1991 Maternal urine 
(n = 1519) n (%) 95% CI (n = 792) n (%) 95% CI P 
Marijuana 27 (1.8) 1.20,2.54 23 (2.9) 1.89,4.26 .11 
Cocaine 5 (0.3) 0.12,0.73 9 (1.1) 0.56,2.08 .04 
Methamphetamines 6 (0.4) 0.16,0.82 5 (0.6) 0.23, 1.39 .65 
Overall* 37 (2.4) 1.75,3.31 35 (4.4) 3.15,6.03 .02 
CI = confidence interval. 
* Unduplicated counts of all samples with at least one positive test. 
immunoassay (SYV A EMIT Drugs of Abuse Reagent 
System, Palo Alto, CAl for amphetamines (cutoff value 
500 ng/g) , cannabinoids (40 ng/g) , and benzoylecognine, 
a cocaine metabolite (75 ng/g). All positives were con-
firmed by gas chromatography/mass spectroscopy. An 
enzyme immunoassay amphetamine-positive sample 
was reported to be methamphetamine positive when the 
gas chromatography/mass spectroscopy detected meth-
amphetamine. Statistical analysis included I" analysis 
for discrete variables, Student two-sided t test for contin-
uous variables, and step-wise logistic regression for mul-
tivariate regression. A Pvalue of < .05 was considered to 
be significant. 
RESULTS 
Meconium samples were collected from 1202 well baby 
nursery infants and 317 NICU infants. The mean ma-
ternal age was 26.3 years; 35% were primigravid; 79% 
were white, non-Hispanic; and 76% had private insur-
ance. The 1991 cohort did not differ from the 2000/2001 
cohort in mean maternal age or percentage of primi-
gravid women. The 2000/2001 cohort had a higher 
percentage of Hispanic women (9% versus 7%, P = .05) 
and more women with private insurance (76% versus 
72%, P = .04) than the 1991 cohort of women. 
Table 1 reports the drug screen results of the 2000/ 
2001 study in comparison with the 1991 maternal urine 
study. There were no significant differences in the rates 
of positivity for methamphetamine or marijuana be-
tween the 1991 and 2000/2001 studies. Cocaine preva-
lence declined from 1.1% in 1991 to 0.3% in 2000/2001 
(P = .04). Overall, the prevalence of positivity for any of 
these three drugs declined over the 10-year period from 
4.4% to 2.4% (P = .02). 
Univariate analysis of the 2000/2001 data was per-
formed comparing maternal and infant characteristics 
between samples positive for cocaine, methamphet-
amine, and/or marijuana and samples negative for those 
drugs (Table 2). There were no significant differences 
between the two groups in regard to maternal age, 
minority status, insurance status, or history of maternal 
alcohol use. Meconium samples positive for cocaine, 
methamphetamine, and/or marijuana were more likely 
to be associated with mothers who were unmarried, had 
a reported history of maternal tobacco use or a history of 
maternal social drug use, and had infants of lower birth 
Table 2. Univariate Analysis of Maternal and Neonatal Factors in Relation to Positivity for Cocaine, Methamphetamine, 
and/or Marijuana of 2000/2001 Meconium Study 
Positive cocaine, Negative cocaine, 
methamphetamine, methamphetamine, Logistic 
and/or marijuana and/or marijuana regression OR 
(n = 37) n (%) 95% CI (n = 1482) n (%) 95% CI P (95% CI) 
Mean maternal age (y) 24.6 22.46,26.74 26.4 26.11,26.69 .07 
Unmarried 13/31 (42) 25.67,59.69 249/1405 (18) 15.79, 19.79 <.001 
Minority 8/33 (24) 11.94,40.89 227/1407 (16) 14.28,18.13 .2 
Medicaid or no 11130 (37) 21.02,54.78 309/1311 (24) 21.65,25.58 .09 
msurance 
History of maternal 14/25 (56) 34.42, 74.26 98/1082 (9) 7.45,10.88 <.001 9.01 (3.45,23.81) 
tobacco use 
History of maternal 2/22 (9) 1.55,26.92 26/1166 (2) 1.49,3.20 .09 
alcohol use 
History of maternal 7/24 (29) 13.74,49.36 15/1166 (1) 0.75,2.07 <.001 13.89 (3.68,52.63) 
social drug use 
Birth weight (g) 2747 2535.2,2958.8 3161 3124.8,3197.2 <.001 
Gestational age (wk) 35.6 34.21,36.99 37.5 37.32,37.68 .003 
CI = confidence interval; OR = odds ratio. 
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Table 3. Drug Prevalence Rates of Well Baby Nursery and Neonatal Intensive Care Unit Cohorts 
WBN NICU 
(n = 1202) n (%) 95% CI (n = 317) n (%) 95% CI P 
Marijuana 17 (1.4) 0.85,2.21 10 (3.2) 1.61,5.55 .05 
Cocaine 3 (0.2) 0.06,0.68 2 (0.6) 0.11,2.07 .33 
Amphetamine 3 (0.2) 0.06,0.68 3 (0.9) 0.24,2.55 .11 
Overall* 23 (1.9) 1.25,2.81 15 (4.7) 2.78,7.51 .008 
WBN = well baby nursery; NICU = neonatal intensive care unit; CI = confidence interval. 
* Unduplicated counts of all samples with at least one positive test. 
weight and younger gestational age. A step-wise logistic 
regression was performed using meconium results for 
cocaine, methamphetamines, or marijuana as the depen-
dent variable and the factors found to be associated with 
positivity with univariate analysis as the independent 
variables. Only a reported history of maternal tobacco 
use and social drug use remained independently associ-
ated with drug positivity. 
A comparison between the well baby nursery and 
NICU cohorts was also performed. There were no dif-
ferences between the cohorts in regard to mean maternal 
age, percentage of primigravid women, and race or 
ethnicity. The NICU cohort had significantly fewer 
women with private insurance (67%) than the well baby 
nursery cohort (79%, P < .0001). The rates of drug 
positivity for the two cohorts are shown in Table 3. The 
prevalence of marijuana-positive samples was higher in 
the NICU cohort (3.2%) than in the well baby nursery 
cohort (1.4%, P = .05). Overall, the prevalence for 
positivity for any of these three drugs was higher in the 
NICU cohort (4.7%) than in the well baby nursery 
cohort (1.9%, P = .008). 
DISCUSSION 
The objectives of this study were to estimate the current 
prevalence of prenatal exposure to methamphetamine 
and other drugs of abuse among infants born in northern 
Utah and to compare those results with those obtained in 
1991. We found a decrease in the prevalence of prenatal 
illicit substance abuse in northern Utah over the last 
decade, as opposed to an increase in prevalence reported 
nationally. The rate of marijuana, cocaine, andlor meth-
amphetamine use among pregnant women in Utah doc-
umented in the 1991 prevalence study was 4.4%; it was 
2.4% in 2000/2001. The National Household Survey on 
Drug Abuse reports that illicit drug use in the United 
States within the past month for women aged 15-44 
years was 6.7% in 1994 and 7.5% in 2000. This same 
data set reports illicit drug use rates among pregnant 
women to be 1.8% in 1994 and 3.3% in 2000.6 The 
National Household Survey relies on self-report of drug 
use and is therefore biased to under-reporting; however, 
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when the same methodology is used over time, the 
reported trends are meaningful. 
Although the study performed in 2000/2001 analyzed 
meconium and not maternal urine, as in the 1991 study, 
this difference in methodology does not impact the find-
ing of a decreasing prevalence. Urine drug screens can 
detect drug metabolites up to 72 hours after use, whereas 
meconium screening can detect use from 20 weeks' 
gestation onward. 7 The fact that the rate of drug detec-
tion decreased when a more sensitive test was used for 
analysis indicates a true decrease in prevalence. 
We were particularly interested in the current preva-
lence of methamphetamine positivity because of the 
rapid increase in its use by women as reported by the 
Utah Division of Substance Abuse.4 The Division col-
lects extensive information on individuals seeking drug 
treatment that includes primary, secondary, and tertiary 
drugs of abuse. From 1992 to 2001, the percentage of 
women reporting methamphetamine to be their primary 
substance of use rose from 1.2% to 37%. We were 
surprised to find no difference in the rate of methamphet-
amine positivity between the 2000/2001 and the 1991 
studies. We do not believe that our study methodology 
can explain this. Meconium analysis is a well-established 
and verified means of drug detection.8 Our samples 
came from the busiest hospitals in northern Utah, includ-
ing six of the seven NICUs in the state. We questioned 
whether the time of year the samples were collected 
(summer through fall) influenced the findings. The sub-
stance abuse specialists in Utah, however, have not 
documented a variable supply of methamphetamine in 
the community from season to season and attribute this 
to the relative ease of its manufacture at the local level. 
Our findings are similar to findings reported by Derauf 
et al in Hawaii, presented at the 2001 Society for Pediat-
ric Research meeting (Derauf C, Katz A, Easa D. The 
prevalence of methamphetamine and other drug use 
during pregnancy [abstract]. Pediatr Res 2001;49:166A). 
They, too, had data based primarily on drug treatment 
admissions that suggested the methamphetamine abuse 
is epidemic in Hawaii. In their anonymous meconium 
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screening study, they found a rate of less than 10f0 for 
methamphetamine. 
We have several theories about the reasons behind the 
lack of increase in methamphetamine-positive newborns 
despite the rise in use in the general female population. 
One reason may be that methamphetamine-abusing 
women have trouble getting pregnant and/or staying 
pregnant. Another may be that methamphetamine-abus-
ing women, once they discover they are pregnant, ab-
stain from use later in pregnancy, and thus the meco-
nium screen will be negative. An explanation supported 
by anecdotal reports from users as reported by the 
Division of Substance Abuse is that methamphetamine 
use often begins after the infant is born, starting with the 
desire to lose weight and gain control, then turning into 
an addiction. Another theory could be that an increase in 
knowledge of clinicians and the general public about 
prenatal substance abuse over the past decade has had a 
positive impact on the prevalence of use during preg-
nancy. Further studies that focus on women of childbear-
ing age who are methamphetamine users may help de-
termine factors that impact their drug use during and 
after pregnancy. 
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